Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors

Clinical trial NCT04650451 · SUSPENDED

Trial details

NCT number: NCT04650451
Sponsor: Bellicum Pharmaceuticals
Status: SUSPENDED
Phase: Phase 1
Study type: INTERVENTIONAL

HER-2 Gene Amplification HER2-positive Gastric Cancer HER2-positive Breast Cancer HER-2 Protein Overexpression Solid Tumor, Adult

Start date: 2020-12-07
Primary completion: 2025-12-31
Enrollment: 220

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.